E-Z-Disk

Manufacturer
E-Z-EM, INC. | Bracco Diagnostics Inc | Confab Laboratories Inc | E-Z-EM Canada Inc
Effective date
2025-09-29
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
10
Source
full-release
Hydrated at
2026-05-31 21:45:03

Label at a glance#

ProductE-Z-Disk
Active ingredientBARIUM SULFATE
Label structure13 sections

Indications and uses

E-Z-DISK is indicated for the evaluation of esophageal patency in adults and pediatric patients aged 12 years and older.

Dosage and administration

The recommended dose of E-Z-DISK in adults and pediatric patients aged 12 years and older is one 700 mg tablet orally during imaging. Swallow one tablet whole with the aid of one or two swallows of water. Do not cut, crush, or chew the tablet. Advise patients to hydrate following the E-Z-DISK imaging procedure [see Warnings and Precautions ( 5.3 )] . E-Z-DISK is formulated to disintegrate within the gastrointestin...

Storage and handling

How Supplied E-Z-DISK (barium sulfate) tablets, 700 mg, are white to lightly colored, between 11.5 mm and 13.5 mm (0.45 inch and 0.53 inch) in diameter, flat-sided disks with EZEM inscribed on one side and 778 on the other side supplied in a glass bottle containing 100 tablets (NDC 10361-778-31). Storage and Handling Store at 20°C to 25°C (68°F to 77° F) [see USP controlled room temperature]. Store in original con...

Label contents#

Full prescribing information#

1  INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

E-Z-DISK is indicated for the evaluation of esophageal patency in adults and pediatric patients aged 12 years and older.

2  DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

The recommended dose of E-Z-DISK in adults and pediatric patients aged 12 years and older is one 700 mg tablet orally during imaging.

Swallow one tablet whole with the aid of one or two swallows of water. Do not cut, crush, or chew the tablet.

Advise patients to hydrate following the E-Z-DISK imaging procedure [see Warnings and Precautions (5.3)].

E-Z-DISK is formulated to disintegrate within the gastrointestinal (GI) tract. In the event of prolonged retention, consider implementing appropriate interventions.

3  DOSAGE FORMS AND STRENGTHS

DOSAGE FORMS & STRENGTHS SECTION

Tablets: 700 mg of barium sulfate as a white to lightly colored, between 11.5 mm and 13.5 mm (0.45 inch and 0.53 inch) in diameter, flat-sided disk with EZEM inscribed on one side and 778 on the other side.

4  CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

E-Z-DISK is contraindicated in patients with:

  • Known severe hypersensitivity to barium sulfate or any of the excipients of E-Z-DISK [see Warnings and Precautions (5.1)]
  • Known, suspected, or high risk of perforation of the GI tract such as patients with a recent GI perforation, acute GI hemorrhage or ischemia, toxic megacolon, severe ileus, recent GI surgery or biopsy, acute GI injury, or recent radiotherapy to the pelvis [see Warnings and Precautions (5.2)]
  • Known obstruction of the GI tract [see Warnings and Precautions (5.3)]
  • High risk of aspiration such as patients with known or suspected tracheoesophageal fistula or obtundation [see Warnings and Precautions (5.4)]

5  WARNINGS AND PRECAUTIONS

WARNINGS AND PRECAUTIONS SECTION

5.1  Hypersensitivity Reactions

SPL UNCLASSIFIED SECTION

E-Z-DISK may induce serious hypersensitivity reactions with manifestations including hypotension, bronchospasm and other respiratory impairments, and dermal reactions including rashes, urticaria and itching. A history of bronchial asthma, atopy, food allergies, or a reaction to a contrast agent may increase the risk for hypersensitivity reactions. E-Z-DISK is contraindicated in patients with known severe hypersensitivity to barium sulfate or any of the excipients of E-Z-DISK [see Contraindications (4)]. Have emergency equipment and trained personnel immediately available during the procedure.

5.2  Intra-abdominal Barium Leakage

SPL UNCLASSIFIED SECTION

Barium leakage from the GI tract has been associated with peritonitis and granuloma formation. Barium sulfate from orally administered E-Z-DISK may leak in the presence of conditions such as carcinomas, GI fistula, inflammatory bowel disease, gastric or duodenal ulcer, appendicitis, or diverticulitis, and in patients with severe stenosis of the GI tract, especially if it is distal to the stomach. E-Z-DISK is contraindicated in patients with known, suspected, or high risk of perforation of the GI tract [see Contraindications (4)].

5.3  Baroliths and Bowel Obstruction

SPL UNCLASSIFIED SECTION

Barium sulfate from orally administered E-Z-DISK may accumulate in the GI tract, causing obstruction or impaction with development of baroliths (inspissated barium associated with feces) and may lead to abdominal pain, appendicitis, or perforation. Patients with the following are at higher risk for developing obstruction or baroliths: severe stenosis at any level of the GI tract, impaired GI motility, electrolyte imbalance, dehydration, low residue diet, medications that delay GI motility, constipation, pediatric patients with cystic fibrosis or Hirschsprung disease, and advanced age. E-Z-DISK is contraindicated in patients with known obstruction of the GI tract [see Contraindications (4)]. To reduce the risk of delayed GI transit and obstruction, maintain adequate hydration after the E-Z-DISK procedure. Monitor patients at risk for delayed gastrointestinal transit for development of signs and symptoms of bowel obstruction.

5.4  Aspiration Pneumonitis

SPL UNCLASSIFIED SECTION

Oral administration of barium is associated with aspiration pneumonitis, especially in patients with a history of food aspiration or with compromised swallowing mechanism. Vomiting following oral administration of barium sulfate may lead to aspiration pneumonitis. E-Z-DISK is contraindicated in patients with high risk of aspiration such as known or suspected tracheoesophageal fistula or obtundation [see Contraindications (4)].

5.5  Systemic Embolization

SPL UNCLASSIFIED SECTION

Barium sulfate from orally administered E-Z-DISK may intravasate into the venous drainage of the GI tract and enter the circulation as a "barium embolus" leading to potentially fatal complications, which include systemic and pulmonary embolism, disseminated intravascular coagulation, septicemia, and prolonged severe hypotension.

6  ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

The following clinically significant adverse reactions are described elsewhere in the labeling:

  • Hypersensitivity Reactions [see Warnings and Precautions (5.1)]
  • Intra-abdominal Barium Leakage [see Warnings and Precautions (5.2)]
  • Baroliths and Bowel Obstruction [see Warnings and Precautions (5.3)]
  • Aspiration Pneumonitis [see Warnings and Precautions (5.4)]

The following adverse reactions associated with the use of E-Z-DISK or other barium sulfate products were identified in postmarketing reports or published clinical studies. Because some of these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or to establish a causal relationship to drug exposure:

Cardiovascular disorders: Vasovagal and syncopal episodes
Gastrointestinal disorders: Barium sulfate impaction, nausea, vomiting, diarrhea, abdominal cramping
Respiratory disorders: Aspiration pneumonitis

Adverse Reactions in Pediatric Patients

No additional safety signals have been reported in pediatric patients aged 12 years and older.

8  USE IN SPECIFIC POPULATIONS

USE IN SPECIFIC POPULATIONS SECTION

8.1  Pregnancy

PREGNANCY SECTION

Risk Summary

Barium sulfate is not absorbed systemically following oral administration, and maternal use is not expected to result in fetal exposure to E-Z-DISK [see Clinical Pharmacology (12.3)]

8.2  Lactation

SPL UNCLASSIFIED SECTION

Risk Summary

Barium sulfate is not absorbed systemically by the mother following oral administration, and breastfeeding is not expected to result in exposure of the infant to E-Z-DISK.

8.4  Pediatric Use

PEDIATRIC USE SECTION

The safety and effectiveness of E-Z-DISK for use in radiographic evaluation of esophageal patency have been established in pediatric patients 12 years and older. Use of E-Z-DISK in this age group for this indication is supported by effectiveness established in studies of adults and pediatric safety data from other barium sulfate products [see Adverse Reactions (6)].

8.5  Geriatric use

GERIATRIC USE SECTION

Reported clinical experience has not identified differences between elderly and younger patients.

11  DESCRIPTION

DESCRIPTION SECTION

E-Z-DISK (barium sulfate) tablet is a radiographic contrast agent for oral use.

Barium sulfate is designated chemically as BaSO4 with molecular weight of 233.4 g/mol, density of 4.5 g/cm3, and the following chemical structure:

formula
formula

E-Z-DISK is a white to lightly colored, flat-sided disk, between 11.5 mm and 13.5 mm (0.45 inch and 0.53 inch) in diameter. Each tablet contains 700 mg barium sulfate and the following inactive ingredients: confectioner’s sugar, microcrystalline cellulose, corn starch, povidone, croscarmellose sodium, and magnesium stearate.

12  CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

12.1  Mechanism of Action

MECHANISM OF ACTION SECTION

E-Z-DISK is formulated to pass through the esophagus into the stomach when the esophageal lumen is greater than 11.5 mm to 13.5 mm (0.45 inch to 0.53 inch) in diameter. Due to its high atomic number, barium is opaque to X-rays and therefore acts as a positive contrast agent for radiographic studies.

12.2  Pharmacodynamics

PHARMACODYNAMICS SECTION

Barium sulfate has no pharmacological effects.

12.3  Pharmacokinetics

PHARMACOKINETICS SECTION

Orally administered barium sulfate passes through the gastrointestinal tract in an unchanged form and is absorbed only in insignificant amounts.

13  NONCLINICAL TOXICOLOGY

NONCLINICAL TOXICOLOGY SECTION

13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

No animal studies have been performed to evaluate the carcinogenic potential of barium sulfate or potential effects on fertility.

16  HOW SUPPLIED/STORAGE AND HANDLING

HOW SUPPLIED SECTION

How Supplied

E-Z-DISK (barium sulfate) tablets, 700 mg, are white to lightly colored, between 11.5 mm and 13.5 mm (0.45 inch and 0.53 inch) in diameter, flat-sided disks with EZEM inscribed on one side and 778 on the other side supplied in a glass bottle containing 100 tablets (NDC 10361-778-31).

Storage and Handling

Store at 20°C to 25°C (68°F to 77° F) [see USP controlled room temperature]. Store in original container and protect from moisture.

17  PATIENT COUNSELING INFORMATION

INFORMATION FOR PATIENTS SECTION

Administration Instructions

Instruct patients to swallow E-Z-DISK as a whole tablet with the aid of one or two swallows of water (do not cut, crush, or chew) [see Dosage and Administration (2.2)].

Hypersensitivity Reactions

Advise patients to seek medical attention for any delayed onset of hypersensitivity such as rash, urticaria, or respiratory difficulty [see Warnings and Precautions (5.1)].

Baroliths and Bowel Obstruction

Advise patients to drink a sufficient amount of water to maintain adequate hydration following the E-Z-DISK procedure and to seek medical attention for signs and symptoms of bowel obstruction [see Warnings and Precautions (5.3)].

Manufactured for
Bracco Diagnostics Inc.
Princeton, NJ 08540

by
Confab Laboratories Inc.
Saint Hubert (Quebec) Canada J3Y 3X3

rev. 08/25      301871-02

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

E-Z-Disk Tablets NDC: 10361-778-3

e-z-disk-unit-label
e-z-disk-unit-label

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
BARIUM SULFATE Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
5dbf91a8-ec29-4ffc-807c-e3bae7fb67b1Product name120201123
85bed648-23ca-4804-98e6-e36aee999cadProduct name120190717
80de93b4-8a94-428d-beb7-d644353ee70bProduct name120180424
eb4f7d5b-1286-40dc-b8bf-ad87ff51c688Product name120170522
db8eb201-78c7-4590-8a71-fac0a539bd8cProduct name120170404
141092be-5eb5-452e-9f69-2d350aa70a87Product name120161208

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
10361-778-31E-Z-Disk100 in 1 BOTTLE, GLASSTABLET10010

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
10361-778-31EA - Each10361-7780f1e4445-59c0-48ff-9e2f-f5cb42717fb112014-09-03

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
BARIUM SULFATEACTIVE INGREDIENT25BB7EKE2E1
BARIUM SULFATEACTIVE MOIETY25BB7EKE2E1

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 2 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
10361-77810361-778-31

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 1 matching rows.

Name, UNII, Kind table
NameUNIIKind
BARIUM SULFATE25BB7EKE2EACTIB

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N219840-001E-Z-DISKBARIUM SULFATE700MGTABLET / ORALRLD, RS2025-08-01

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08N219840-001E-Z-DISK700MGTABLET / ORALRLD, RS2025-08-0184e616aacf4f…
2026-08-18 06:07:402026-07N219840-001E-Z-DISK700MGTABLET / ORALRLD, RS2025-08-01caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N219840-001E-Z-DISK700MGTABLET / ORALRLD, RS2025-08-01011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N219840-001E-Z-DISK700MGTABLET / ORALRLD, RS2025-08-0131067a03dcf5…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06N219840-001E-Z-DISK700MGTABLET / ORALRLD, RS2025-08-01a50c72e98297…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
E-Z-DiskBARIUM SULFATEE-Z-EM, INC.c759668b-5cf1-b237-00c8-a5e4733b6f4c2025-09-29Warnings, Adverse reactionsExact identifier
ndc (package): 10361-778-31
ndc (product): 10361-778
ndc11 (package): 10361077831
spl id: 29014e07-78d9-38c1-1945-8cb44ec6f69b
spl set id: c759668b-5cf1-b237-00c8-a5e4733b6f4c

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.